4MU7
| Crystal structure of cIAP1 BIR3 bound to T3450325 | Descriptor: | (3S,10aS)-2-[(2S)-2-cyclohexyl-2-{[(2S)-2-(methylamino)butanoyl]amino}acetyl]-N-[(4R)-3,4-dihydro-2H-chromen-4-yl]-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole-3-carboxamide, Baculoviral IAP repeat-containing protein 2, ZINC ION | Authors: | Snell, G.P, Dougan, D.R. | Deposit date: | 2013-09-20 | Release date: | 2013-12-11 | Last modified: | 2024-02-28 | Method: | X-RAY DIFFRACTION (1.79 Å) | Cite: | Design, synthesis, and biological activities of novel hexahydropyrazino[1,2-a]indole derivatives as potent inhibitors of apoptosis (IAP) proteins antagonists with improved membrane permeability across MDR1 expressing cells. Bioorg.Med.Chem., 21, 2013
|
|
1BK1
| ENDO-1,4-BETA-XYLANASE C | Descriptor: | ENDO-1,4-B-XYLANASE C | Authors: | Fushinobu, S, Ito, K, Konno, M, Wakagi, T, Matsuzawa, H. | Deposit date: | 1998-07-14 | Release date: | 1999-01-13 | Last modified: | 2024-10-30 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Crystallographic and mutational analyses of an extremely acidophilic and acid-stable xylanase: biased distribution of acidic residues and importance of Asp37 for catalysis at low pH. Protein Eng., 11, 1998
|
|
3VNT
| Crystal Structure of the Kinase domain of Human VEGFR2 with a [1,3]thiazolo[5,4-b]pyridine derivative | Descriptor: | 1,2-ETHANEDIOL, 2-chloro-3-(1-cyanocyclopropyl)-N-[5-({2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}oxy)-2-fluorophenyl]benzamide, Vascular endothelial growth factor receptor 2 | Authors: | Oki, H. | Deposit date: | 2012-01-17 | Release date: | 2012-04-11 | Last modified: | 2024-03-20 | Method: | X-RAY DIFFRACTION (1.64 Å) | Cite: | Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds J.Med.Chem., 55, 2012
|
|
3W32
| EGFR kinase domain complexed with compound 20a | Descriptor: | 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-N-[2-(methylsulfonyl)ethyl]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxamide, Epidermal growth factor receptor, SULFATE ION | Authors: | Sogabe, S, Kawakita, Y. | Deposit date: | 2012-12-07 | Release date: | 2013-03-06 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (1.8 Å) | Cite: | Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors Bioorg.Med.Chem., 21, 2013
|
|
3W33
| EGFR kinase domain complexed with compound 19b | Descriptor: | 4-{[4-(1-benzothiophen-4-yloxy)-3-chlorophenyl]amino}-N-(2-hydroxyethyl)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxamide, Epidermal growth factor receptor, SULFATE ION | Authors: | Sogabe, S, Kawakita, Y. | Deposit date: | 2012-12-07 | Release date: | 2013-03-06 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (1.7 Å) | Cite: | Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors Bioorg.Med.Chem., 21, 2013
|
|
3WIY
| Crystal structure of Mcl-1 in complex with compound 10 | Descriptor: | 7-(4-{[(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrophenyl)sulfonyl]carbamoyl}-2-methylphenyl)-3-[3-(naphthalen-1-yloxy)propyl]pyrazolo[1,5-a]pyridine-2-carboxylic acid, Induced myeloid leukemia cell differentiation protein Mcl-1 | Authors: | Sogabe, S, Igaki, S, Hayano, Y. | Deposit date: | 2013-09-26 | Release date: | 2013-11-27 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (2.15 Å) | Cite: | Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins. J.Med.Chem., 56, 2013
|
|
3WIZ
| Crystal structure of Bcl-xL in complex with compound 10 | Descriptor: | 7-(4-{[(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrophenyl)sulfonyl]carbamoyl}-2-methylphenyl)-3-[3-(naphthalen-1-yloxy)propyl]pyrazolo[1,5-a]pyridine-2-carboxylic acid, Bcl-2-like protein 1, PHOSPHATE ION | Authors: | Sogabe, S, Igaki, S, Hayano, Y. | Deposit date: | 2013-09-26 | Release date: | 2013-11-27 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (2.45 Å) | Cite: | Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins. J.Med.Chem., 56, 2013
|
|
3WIX
| Crystal structure of Mcl-1 in complex with compound 4 | Descriptor: | 7-(4-carboxyphenyl)-3-[3-(naphthalen-1-yloxy)propyl]pyrazolo[1,5-a]pyridine-2-carboxylic acid, Induced myeloid leukemia cell differentiation protein Mcl-1 | Authors: | Sogabe, S, Igaki, S, Hayano, Y. | Deposit date: | 2013-09-26 | Release date: | 2013-11-27 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins. J.Med.Chem., 56, 2013
|
|
3W2S
| EGFR kinase domain with compound4 | Descriptor: | 1-{3-[2-chloro-4-({5-[2-(2-hydroxyethoxy)ethyl]-5H-pyrrolo[3,2-d]pyrimidin-4-yl}amino)phenoxy]phenyl}-3-cyclohexylurea, Epidermal growth factor receptor, SULFATE ION | Authors: | Sogabe, S, Kawakita, Y, Igaki, S. | Deposit date: | 2012-12-03 | Release date: | 2013-01-16 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors. Acs Med.Chem.Lett., 4, 2013
|
|
3W2O
| EGFR Kinase domain T790M/L858R Mutant with TAK-285 | Descriptor: | Epidermal growth factor receptor, N-{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methylbutanamide | Authors: | Sogabe, S, Kawakita, Y, Igaki, S. | Deposit date: | 2012-12-03 | Release date: | 2013-01-16 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (2.35 Å) | Cite: | Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors. Acs Med.Chem.Lett., 4, 2013
|
|
3W2R
| EGFR Kinase domain T790M/L858R mutant with compound 4 | Descriptor: | 1,2-ETHANEDIOL, 1-{3-[2-chloro-4-({5-[2-(2-hydroxyethoxy)ethyl]-5H-pyrrolo[3,2-d]pyrimidin-4-yl}amino)phenoxy]phenyl}-3-cyclohexylurea, Epidermal growth factor receptor | Authors: | Sogabe, S, Kawakita, Y, Igaki, S. | Deposit date: | 2012-12-03 | Release date: | 2013-01-16 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (2.05 Å) | Cite: | Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors. Acs Med.Chem.Lett., 4, 2013
|
|
3W2Q
| EGFR kinase domain T790M/L858R mutant with HKI-272 | Descriptor: | 2-(N-MORPHOLINO)-ETHANESULFONIC ACID, Epidermal growth factor receptor, N-(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)butanamide | Authors: | Sogabe, S, Kawakita, Y, Igaki, S. | Deposit date: | 2012-12-03 | Release date: | 2013-01-16 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (2.2 Å) | Cite: | Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors. Acs Med.Chem.Lett., 4, 2013
|
|
3W2P
| EGFR Kinase domain T790M/L858R mutant with compound 2 | Descriptor: | Epidermal growth factor receptor, N-{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-4-(dimethylamino)butanamide | Authors: | Sogabe, S, Kawakita, Y, Igaki, S. | Deposit date: | 2012-12-03 | Release date: | 2013-01-16 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (2.05 Å) | Cite: | Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors. Acs Med.Chem.Lett., 4, 2013
|
|
1HQY
| Nucleotide-Dependent Conformational Changes in a Protease-Associated ATPase HslU | Descriptor: | ADENOSINE-5'-DIPHOSPHATE, HEAT SHOCK LOCUS HSLU, HEAT SHOCK LOCUS HSLV | Authors: | Wang, J, Song, J.J, Seong, I.S, Franklin, M.C, Kamtekar, S, Eom, S.H, Chung, C.H. | Deposit date: | 2000-12-20 | Release date: | 2001-11-14 | Last modified: | 2024-02-07 | Method: | X-RAY DIFFRACTION (2.8 Å) | Cite: | Nucleotide-dependent conformational changes in a protease-associated ATPase HsIU. Structure, 9, 2001
|
|
1HT1
| Nucleotide-Dependent Conformational Changes in a Protease-Associated ATPase HslU | Descriptor: | ADENOSINE-5'-DIPHOSPHATE, HEAT SHOCK LOCUS HSLU, HEAT SHOCK LOCUS HSLV | Authors: | Wang, J, Song, J.J, Seong, I.S, Franklin, M.C, Kamtekar, S, Eom, S.H, Chung, C.H. | Deposit date: | 2000-12-27 | Release date: | 2001-11-14 | Last modified: | 2024-02-07 | Method: | X-RAY DIFFRACTION (2.8 Å) | Cite: | Nucleotide-dependent conformational changes in a protease-associated ATPase HsIU. Structure, 9, 2001
|
|
1HT2
| Nucleotide-Dependent Conformational Changes in a Protease-Associated ATPase HslU | Descriptor: | ADENOSINE-5'-DIPHOSPHATE, HEAT SHOCK LOCUS HSLU, HEAT SHOCK LOCUS HSLV | Authors: | Wang, J, Song, J.J, Seong, I.S, Franklin, M.C, Kamtekar, S, Eom, S.H, Chung, C.H. | Deposit date: | 2000-12-27 | Release date: | 2001-11-14 | Last modified: | 2024-02-07 | Method: | X-RAY DIFFRACTION (2.8 Å) | Cite: | Nucleotide-dependent conformational changes in a protease-associated ATPase HsIU. Structure, 9, 2001
|
|
7C6B
| Crystal structure of Ago2 MID domain in complex with 6-(3-(2-carboxyethyl)phenyl)purine riboside monophosphate | Descriptor: | 3-[3-[9-[(2R,3R,4S,5R)-3,4-bis(oxidanyl)-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl]phenyl]propanoic acid, PHOSPHATE ION, Protein argonaute-2 | Authors: | Suzuki, M, Takahashi, Y, Saito, J, Miyagi, H, Shinohara, F. | Deposit date: | 2020-05-21 | Release date: | 2020-11-25 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.7 Å) | Cite: | siRNA potency enhancement via chemical modifications of nucleotide bases at the 5'-end of the siRNA guide strand. Rna, 27, 2021
|
|
7D7U
| Crystal structure of Ago2 MID domain in complex with 8-Br-adenosin-5'-monophosphate | Descriptor: | 8-BROMO-ADENOSINE-5'-MONOPHOSPHATE, Protein argonaute-2 | Authors: | Suzuki, M, Takahashi, Y, Saito, J, Miyagi, H, Shinohara, F. | Deposit date: | 2020-10-06 | Release date: | 2020-11-25 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | siRNA potency enhancement via chemical modifications of nucleotide bases at the 5'-end of the siRNA guide strand. Rna, 27, 2021
|
|
1IW9
| Crystal Structure of the M Intermediate of Bacteriorhodopsin | Descriptor: | 2,3-DI-O-PHYTANLY-3-SN-GLYCERO-1-PHOSPHORYL-3'-SN-GLYCEROL-1'-PHOSPHATE, 2,3-DI-PHYTANYL-GLYCEROL, RETINAL, ... | Authors: | Takeda, K, Matsui, Y, Kamiya, N, Adachi, S, Okumura, H, Kouyama, T, RIKEN Structural Genomics/Proteomics Initiative (RSGI) | Deposit date: | 2002-04-25 | Release date: | 2003-12-23 | Last modified: | 2024-10-30 | Method: | X-RAY DIFFRACTION (2.5 Å) | Cite: | Crystal structure of the M intermediate of bacteriorhodopsin: allosteric structural changes mediated by sliding movement of a transmembrane helix J.Mol.Biol., 341, 2004
|
|
6DUY
| |
6DUW
| |
6DV1
| |